

This document applies to the following:

Formulary	Applies
Standard Control (SF)	☒
Standard Control – Choice (SCCF)	☒
Preferred Drug Plan Design (PDPD)	☐
Advanced Control Specialty (ACSF)	☐
Advanced Control Specialty – Choice (ACSCF)	☐
Managed Medicaid Template (MMT)	☐
Marketplace (MF)	☐
Aetna Small Group Affordable Care Act (SG ACA)	☐
Aetna Health Exchange (AHE)	☐
Aetna Individual Lives (IVL)	☐
Value (VF)	☐

Formulary	Applies
New to Market (NTM)	☐
Standard Formulary Chart (SFC)	☐
Basic Control Chart Preferred Drug Plan Design (BCC PDPD)	☐
Advanced Control Specialty Formulary Chart (ACSFC)	☐
Value Formulary Chart (VFC)	☐
Medical Benefit	☐
Medical Benefit: Advanced Biosimilars First	☐
Medical Benefit: Managed Medicaid (MMMB)	☐
Medicare Part B	☐
Medicare Part B: Advanced Biosimilars First	☐

Exceptions Criteria

Multiple Sclerosis

This document informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

These criteria were developed to align with the following: Standard Control Formulary (SF) and Standard Control Choice Formulary (SCCF).

Plan Design Summary

This program applies to the multiple sclerosis products specified in this document. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred products and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to all members requesting treatment with Aubagio, Copaxone 20 mg, Extavia, Gilenya, Tascenso ODT, Tecfidera or Vumerity. This program also applies to members requesting treatment with Briumvi or Lemtrada for the first time.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Multiple Sclerosis (MS) Products

Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

	Product(s)
Preferred	• Avonex (interferon beta-1a) • Bafiertam (monomethyl fumarate) • Betaseron (interferon beta-1b) • Copaxone 40 mg (glatiramer acetate) • dimethyl fumarate (generic) • fingolimod (generic) • glatiramer acetate (generic) • Glatopa (glatiramer acetate) • Kesimpta (ofatumumab) • Mayzent (siponimod) • Ocrevus (ocrelizumab) • Rebif (interferon beta-1a) • teriflunomide (generic) • Tysabri (natalizumab) • Zeposia (ozanimod)
Target	• Aubagio (teriflunomide) • Briumvi (ublituximab-xiiy) • Copaxone 20 mg (glatiramer acetate) • Extavia (interferon beta-1b) • Gilenya (fingolimod) • Lemtrada (alemtuzumab) • Tascenso ODT (fingolimod) • Tecfidera (dimethyl fumarate) • Vumerity (diroximel fumarate)

Exception Criteria

This program applies to members requesting treatment for an indication that is FDA-approved for the preferred products.

Aubagio

Coverage for Aubagio is provided when both of the following criteria are met:

Reference number(s)
6645-D

- Member has had a documented intolerable adverse event to generic teriflunomide, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.
- Member has a documented inadequate response or intolerable adverse event with at least two of the preferred products other than generic teriflunomide.

Briumvi

Coverage for Briumvi is provided when either of the following criteria is met:

- Member is currently receiving therapy with Briumvi, excluding when Briumvi is obtained as samples or via manufacturer's patient assistant programs.
- Member meets both of the following criteria:
 - Member has had a documented intolerable adverse event to Kesimpta or Ocrevus.
 - Member has a documented inadequate response or intolerable adverse event with at least two of the preferred products other than Kesimpta or Ocrevus.

Copaxone 20 mg

Coverage for Copaxone 20 mg is provided when both of the following criteria are met:

- Member has had a documented intolerable adverse event to generic glatiramer acetate, Glatopa, or Copaxone 40 mg, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.
- Member has a documented inadequate response or intolerable adverse event with at least two of the preferred products other than generic glatiramer acetate, Glatopa, or Copaxone 40 mg.

Extavia

Coverage for Extavia is provided when both of the following criteria are met:

- There is a documented clinical reason that the member must use Extavia over Betaseron. (Please note that Extavia and Betaseron are the exact same products with different labels and brand names.)
- Member has a documented inadequate response or intolerable adverse event with at least two of the preferred products other than Betaseron.

Gilenya or Tascenso ODT

Coverage for Gilenya or Tascenso ODT is provided when both of the following criteria are met:

- Member meets either of the following criteria:
 - Member has had a documented intolerable adverse event to generic fingolimod, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.

Reference number(s)
6645-D

- The requested product is Tascenso ODT and the member is unable to swallow generic fingolimod capsules.
- Member meets either of the following criteria:
 - Member has had a documented inadequate response or intolerable adverse event with at least two of the preferred products other than generic fingolimod.
 - Member is less than 18 years of age.

Lemtrada

Coverage for Lemtrada is provided when either of the following criteria is met:

- Member is currently receiving therapy with Lemtrada, excluding when Lemtrada is obtained as samples or via manufacturer's patient assistance programs.
- Member has a documented inadequate response or intolerable adverse event with at least three of the preferred products.

Tecfidera

Coverage for Tecfidera is provided when both of the following criteria are met:

- Member has had a documented intolerable adverse event to generic dimethyl fumarate, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.
- Member has a documented inadequate response or intolerable adverse event with at least two of the preferred products other than generic dimethyl fumarate.

Vumerity

Coverage for Vumerity is provided when both of the following criteria are met:

- Member has a documented intolerable adverse event to generic dimethyl fumarate (including intolerable gastrointestinal adverse event from dimethyl fumarate) or Bafiertam.
- Member has a documented inadequate response or intolerable adverse event with at least two of the preferred products other than dimethyl fumarate or Bafiertam.

References

1. Aubagio [package insert]. Cambridge, MA: Genzyme Corporation; June 2024.
2. Avonex [package insert]. Cambridge, MA: Biogen Inc.; July 2023.
3. Bafiertam [package insert]. High Point, NC: Banner Life Sciences LLC.; March 2024.
4. Betaseron [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; July 2023.
5. Briumvi [package insert]. Morrisville, NC: TG Therapeutics, Inc.; November 2024.
6. Copaxone [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; November 2023.
7. Dimethyl fumarate [package insert]. Bridgewater, NJ: Amneal Pharmaceuticals LLC.; June 2024.

Reference number(s)
6645-D

8. Extavia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation.; July 2023.
9. Fingolimod [package insert]. Dongguan, China: Sunshine Lake Pharma Co., Ltd.; October 2024.
10. Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2024.
11. Glatiramer acetate 20mg/mL [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; January 2024.
12. Glatiramer acetate 40mg/mL [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; January 2024.
13. Glatopa [package insert]. Princeton, NJ: Sandoz Inc.; December 2023.
14. Kesimpta [package insert]. East Hanover, NJ: Novartis; April 2024.
15. Lemtrada [package insert]. Cambridge, MA: Genzyme Corporation; May 2024.
16. Mayzent [package insert]. East Hanover, NJ: Novartis; June 2024.
17. Ocrevus [package insert]. South San Francisco, CA: Genentech, Inc.; June 2024.
18. Rebif [package insert]. Rockland, MA: EMD Serono Inc.; July 2023.
19. Tascenso ODT [package insert]. Swindon, UK: Catalent Pharma Solutions (UK).; July 2024.
20. Tecfidera [package insert]. Cambridge, MA: Biogen Inc.; March 2024.
21. Teriflunomide [package insert]. East Windsor, NJ: Aurobindo Pharma Limited; October 2024.
22. Tysabri [package insert]. Cambridge, MA: Biogen Idec, Inc; October 2023.
23. Vumerity [package insert]. Cambridge, MA: Biogen Inc.; September 2024.
24. Zeposia [package insert]. Summit, NJ: Celgene Corp.; August 2024.